细胞疗法治疗呼吸道病毒感染现状:对COVID-19的适用性
本文综述了以间充质干细胞(MSC)为主的细胞疗法在呼吸道病毒感染所致肺损伤中的临床前数据与机制,并梳理了针对COVID-19快速增加的临床研究。临床前有限数据显示全身给予MSC可显著减轻H5N1和H9N2流感病毒诱导的肺损伤,但尚无冠状病毒呼吸道感染模型数据。COVID-19细胞疗法研究在细胞来源、剂量、给药策略和目标人群上差异很大,需基于临床前证据制定合理策略。
要点
- MSC在ARDS中显示安全性和可能疗效,但在病毒性ARDS中研究不足
- 临床前数据仅显示MSC可减轻H5N1和H9N2流感诱导的肺损伤
- 尚无冠状病毒呼吸道感染模型的MSC数据,COVID-19研究异质性大
核心结论
- 细胞疗法(主要为MSC)在ARDS中显示安全性和可能疗效,但在呼吸道病毒诱导的ARDS中研究不足。
- 有限临床前数据显示全身MSC给药可显著减轻H5N1和H9N2流感病毒诱导的肺损伤。
- 尚无冠状病毒呼吸道感染模型的可用数据,COVID-19细胞疗法临床研究快速增加但异质性大。
研究设计与样本
- 综述类文章,汇总临床前研究、 postulated 机制及当前临床研究。
主要发现
- MSC在ARDS患者中已显示安全性和可能疗效,但未在病毒性ARDS中充分研究。
- 临床前数据表明全身MSC给药可显著减轻H5N1和H9N2流感病毒诱导的肺损伤。
- 尚无冠状病毒呼吸道感染模型的数据。
- COVID-19细胞疗法临床研究使用多种细胞来源、剂量、给药策略和目标人群。
临床怎么用
- 需理解呼吸道病毒诱导肺损伤中MSC作用的临床前研究和推定机制,以制定最大化治疗潜力的合理策略。
局限性
- 缺乏冠状病毒呼吸道感染模型的临床前数据。
- COVID-19细胞疗法临床研究在细胞来源、剂量、给药策略和目标人群上差异大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.
引用
- Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020. PMID: 32265310. doi:10.1183/13993003.00858-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。